Centessa Pharmaceuticals (CNTA) Return on Capital Employed (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Return on Capital Employed of 40.87% for Q1 2026, down 381.0% year-over-year from 14.54% in Q1 2025, and down 3.3% on a QoQ basis from 39.56% in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 6 years of Return on Capital Employed data on file, last reported at 40.87% in Q1 2026.
- Quarterly Return on Capital Employed fell 381.0% year-over-year to 40.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.87% (down 381.0% YoY) and the FY2025 annual result came in at 35.25%, up 1373.0% from the prior year.
- Return on Capital Employed fell to 40.87% in Q1 2026 per CNTA's latest filing, from 39.56% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 33.02% in Q1 2022 and bottomed at 52.72% in Q1 2023.
- The 5-year median for Return on Capital Employed is 46.16% (2024), against an average of 44.59%.
- The widest annual swing landed in 2023, when Return on Capital Employed slumped 1970 bps; it then soared 1692 bps in 2024.
- Tracing CNTA's Return on Capital Employed over 5 years: stood at 50.12% in 2022, then dropped by 4 bps to 52.0% in 2023, then grew by 28 bps to 37.56% in 2024, then slipped by 5 bps to 39.56% in 2025, then decreased by 3 bps to 40.87% in 2026.
- Per Business Quant, the three latest CNTA Return on Capital Employed figures stand at 40.87% (Q1 2026), 39.56% (Q4 2025), and 48.47% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -40.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.87% |
| Dec 31, 2025 | -39.56% |
| Sep 30, 2025 | -48.47% |
| Jun 30, 2025 | -42.98% |
| Mar 31, 2025 | -37.06% |
| Dec 31, 2024 | -37.56% |
| Sep 30, 2024 | -33.83% |
| Jun 30, 2024 | -46.16% |
| Mar 31, 2024 | -50.03% |
| Dec 31, 2023 | -52.00% |
| Sep 30, 2023 | -50.75% |
| Jun 30, 2023 | -51.17% |
| Mar 31, 2023 | -52.72% |
| Dec 31, 2022 | -50.12% |
| Sep 30, 2022 | -49.56% |
| Jun 30, 2022 | -42.13% |
| Mar 31, 2022 | -33.02% |
| Dec 31, 2021 | -62.74% |
| Sep 30, 2021 | -53.24% |